Business
ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial
About this update from Adma Biologics Inc
[{"type":"text","content":"RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation was made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference. The abstract and poster presentation detailed the use of ASCENIV TM, a novel intravenous immune globulin (IGIV) human-slra, as concomitant therapy in a 70-year-old African American male with a history of bronchiectasis who presented with severe respiratory viral disease and confirmed COVID-19 infection. In the abstract and poster presentation, ADMA described the use of ASCENIV as concomitant therapy in an adult hospitalized with COVID-19 infection and rapidly progressive acute respiratory distress syndrome (ARDS). A 70-year-old African American male with history of bronchiectasis presented to the emergency department with a one-week history of increasing dyspnea, dry cough, sudden onset of high-grade fevers, and body chills. The patient was initiated on broad-spectrum anti-infectives and steroids. Initial blood chemistries were unremarkable, pan cultures were negative but a COVID-19 diagnostic was confirmed positive. The patient’s respiratory status deteriorated over the next week with continued progression of pneumonia requiring mechanical ventilation. On Day 11, the patient was initiated on ASCENIV at 1500 mg/kg. In the days following, the patient developed high-grade fevers, prompting modification of anti-infectives and a second dose of ASCENIV at 750 mg/kg. Over the next several days, respiratory function improved, prompting extubation, but complications with a bout of severe tachypnea and declined respiratory function led to temporary re-intubation. With continued clinical management, the patient’s respiratory status steadily improved, warranting extubation and transition to rehabilitation with a confirmed negative COVID-19 test result, no documented co-infections, reduced inflammatory markers, and recovery of lung function. This case documents the clinical outcome of a multi-modality therapeutic approach with broad-spectrum anti-infectives and concomitant ASCENIV...